Baidu
map

FDA批准tob-非格司亭治疗肿瘤患者严重中性粒细胞减少症

2012-08-30 沐雨译 医学论坛网

  2012年8月29日,美国FDA批准tob-非格司亭用于特定接受化疗的患者减少严重中性粒细胞减少症。   Tob-非格司亭拟用于血液或骨髓肿瘤(非髓性恶性肿瘤)服用化疗药物导致骨髓中性粒细胞产生严重下降的成人患者,中性粒细胞的减少可能导致感染和发热(发热性中性粒细胞减少症)。   Tob-非格司亭可刺激骨髓产生中性粒细胞增加,用法是在化疗后前24小时注射。其疗效在一项纳入348例接受抗癌药

  2012年8月29日,美国FDA批准tob-非格司亭用于特定接受化疗的患者减少严重中性粒细胞减少症。

  Tob-非格司亭拟用于血液或骨髓肿瘤(非髓性恶性肿瘤)服用化疗药物导致骨髓中性粒细胞产生严重下降的成人患者,中性粒细胞的减少可能导致感染和发热(发热性中性粒细胞减少症)。

  Tob-非格司亭可刺激骨髓产生中性粒细胞增加,用法是在化疗后前24小时注射。其疗效在一项纳入348例接受抗癌药物多柔比星和多西紫杉醇治疗的成年晚期乳腺癌患者,随机给与tob-非格司亭、安慰剂或非美国批准的非格司亭制剂治疗。试验结果表明,接受tob-非格司亭治疗的患者严重中性粒细胞减少症恢复时间为1.1天,安慰剂治疗者为3.8天。

  在3项包括680例接受大剂量化疗导致骨髓细胞减少(骨髓根除化疗)的乳腺癌、肺癌或非霍奇金淋巴瘤患者的临床试验评价了tob-非格司亭的安全性,其最长久的副作用是骨痛。

    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003860, encodeId=ad45200386061, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu Jun 06 23:36:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981841, encodeId=eba11981841c4, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Dec 06 11:36:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839182, encodeId=6bf018391829b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 06 03:36:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296590, encodeId=0e5112965905d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424114, encodeId=88ca14241142c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003860, encodeId=ad45200386061, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu Jun 06 23:36:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981841, encodeId=eba11981841c4, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Dec 06 11:36:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839182, encodeId=6bf018391829b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 06 03:36:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296590, encodeId=0e5112965905d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424114, encodeId=88ca14241142c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003860, encodeId=ad45200386061, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu Jun 06 23:36:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981841, encodeId=eba11981841c4, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Dec 06 11:36:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839182, encodeId=6bf018391829b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 06 03:36:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296590, encodeId=0e5112965905d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424114, encodeId=88ca14241142c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=)]
    2012-11-06 bugit
  4. [GetPortalCommentsPageByObjectIdResponse(id=2003860, encodeId=ad45200386061, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu Jun 06 23:36:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981841, encodeId=eba11981841c4, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Dec 06 11:36:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839182, encodeId=6bf018391829b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 06 03:36:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296590, encodeId=0e5112965905d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424114, encodeId=88ca14241142c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2003860, encodeId=ad45200386061, content=<a href='/topic/show?id=3f43e621302' target=_blank style='color:#2F92EE;'>#粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76213, encryptionId=3f43e621302, topicName=粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Thu Jun 06 23:36:00 CST 2013, time=2013-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981841, encodeId=eba11981841c4, content=<a href='/topic/show?id=311822199b6' target=_blank style='color:#2F92EE;'>#中性粒细胞减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22199, encryptionId=311822199b6, topicName=中性粒细胞减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Dec 06 11:36:00 CST 2012, time=2012-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839182, encodeId=6bf018391829b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 06 03:36:00 CST 2012, time=2012-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296590, encodeId=0e5112965905d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424114, encodeId=88ca14241142c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Sep 01 06:36:00 CST 2012, time=2012-09-01, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map